HalfLifeDBEvidence before certainty.

4-AcO-DMT evidence profile

The literature supports metabolism of 4-AcO-DMT, also called psilacetin, toward psilocin and includes preclinical prodrug work.

Category: psychedelic · Updated: August 7, 2026

Sources and model notes are maintained by . This page is educational, not clinical guidance. Corrections: admin@halflifedb.co.

Model statusNo curve publishedCurrent sources do not support one defensible human input
Evidence boundarySource note onlyNo animal, forensic, mixture, or proxy value is presented as a human half-life
Model scopeNot modeledThe profile explains what the available records can and cannot establish
References3Linked studies, labels, reviews, or identity records described below

4-AcO-DMT: evidence and interpretation notes

Why HalfLifeDB does not plot 4-AcO-DMT

The literature supports metabolism of 4-AcO-DMT, also called psilacetin, toward psilocin and includes preclinical prodrug work. It does not yet support one route-neutral human half-life for the parent compound.

What each source contributes

  • PubChem: 4-AcO-DMT. This identity record confirms names and compound identity and does not supply a human half-life.
  • Tentative identification of in vitro metabolites of O-acetylpsilocin. This metabolism study identifies pathways, metabolites, or analytical targets and does not by itself create a complete human concentration-time curve.
  • In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin. This supporting literature record adds compound-specific background and is used only within the limits of its design.

For 4-AcO-DMT, the decision to withhold a curve turns on the limits visible in Tentative identification of in vitro metabolites of O-acetylpsilocin. This metabolism study identifies pathways, metabolites, or analytical targets, but it does not by itself create a complete human concentration-time curve.

What evidence would change the page

The next useful evidence for 4-AcO-DMT would be a direct human pharmacokinetic study with a defined exposure context and sufficient late sampling. Without that, converting Tentative identification of in vitro metabolites of O-acetylpsilocin into a first-order midpoint would overstate what its design can support.

InterpretationCategory context and evidence limits

psychedelic context

Psychedelic duration is shaped by pharmacodynamics as well as pharmacokinetics, so subjective effects may not track a simple elimination curve.

  • The curve does not predict psychological effects or functional safety.
  • Metabolites and downstream receptor activity are not separately modeled.
  • Published estimates may come from small or specialized study populations.
EvidenceSource trail and model decision

Sources and evidence context

A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.

2 PubMed0 PMC0 DailyMed1 PubChem
  1. Identity record PubChem Compound Summary: 4-AcO-DMT.
    Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
  2. Research abstract PubMed: Tentative identification of in vitro metabolites of O-acetylpsilocin.
    In vitro metabolism study; included as indirect context, not as a direct human half-life estimate.
  3. Research abstract PubMed: In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin.
    Supporting literature record. Its role and study design should be read from the linked source before applying any numerical finding.
BoundariesWhat this page cannot answer and where to continue

What this page does not answer

  • It does not estimate impairment, intoxication, or fitness to drive.
  • It does not predict urine, blood, saliva, or hair test results.
  • It does not model repeated exposure, tolerance, withdrawal, or interactions.
  • It does not replace clinician, pharmacist, toxicologist, or emergency guidance.

Continue with context

Read the medical disclaimer, methodology, and research standards before using the model for comparison.